4,899 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Acquired by Maverick Capital Ltd.

Maverick Capital Ltd. bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the first quarter, Holdings Channel.com reports. The fund bought 4,899 shares of the medical research company’s stock, valued at approximately $1,420,000.

Several other hedge funds have also recently added to or reduced their stakes in CRL. Fred Alger Management LLC acquired a new position in Charles River Laboratories International in the first quarter valued at approximately $26,000. Harbor Investment Advisory LLC acquired a new position in Charles River Laboratories International in the first quarter valued at approximately $29,000. Berman Capital Advisors LLC boosted its holdings in Charles River Laboratories International by 42.6% in the fourth quarter. Berman Capital Advisors LLC now owns 144 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 43 shares in the last quarter. Huntington National Bank boosted its holdings in Charles River Laboratories International by 121.8% in the first quarter. Huntington National Bank now owns 122 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 67 shares in the last quarter. Finally, Valeo Financial Advisors LLC acquired a new position in Charles River Laboratories International in the first quarter valued at approximately $35,000. Hedge funds and other institutional investors own 92.50% of the company’s stock.

CRL has been the subject of a number of research analyst reports. Citigroup upped their price target on Charles River Laboratories International from $350.00 to $355.00 and gave the company a “neutral” rating in a report on Friday, May 28th. JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $375.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, May 28th. Robert W. Baird reissued a “buy” rating on shares of Charles River Laboratories International in a report on Monday, May 31st. Truist Securities increased their price objective on Charles River Laboratories International from $324.00 to $369.00 and gave the company a “buy” rating in a report on Tuesday, May 25th. Finally, KeyCorp increased their price objective on Charles River Laboratories International from $340.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, May 14th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Charles River Laboratories International presently has an average rating of “Buy” and an average target price of $347.85.

Charles River Laboratories International stock opened at $385.77 on Thursday. Charles River Laboratories International, Inc. has a 12 month low of $192.13 and a 12 month high of $386.57. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.77 and a quick ratio of 1.53. The business’s 50 day moving average is $354.90. The stock has a market capitalization of $19.38 billion, a PE ratio of 52.27, a PEG ratio of 2.76 and a beta of 1.14.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Monday, May 3rd. The medical research company reported $2.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.19 by $0.34. The business had revenue of $824.60 million during the quarter, compared to analysts’ expectations of $798.52 million. Charles River Laboratories International had a return on equity of 22.54% and a net margin of 12.33%. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.84 earnings per share. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.99 EPS for the current fiscal year.

In other Charles River Laboratories International news, Director George Massaro sold 3,370 shares of the stock in a transaction on Thursday, May 6th. The stock was sold at an average price of $336.96, for a total value of $1,135,555.20. Following the completion of the transaction, the director now owns 7,169 shares in the company, valued at $2,415,666.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David Ross Smith sold 3,305 shares of the stock in a transaction on Tuesday, May 4th. The stock was sold at an average price of $340.01, for a total value of $1,123,733.05. Following the completion of the transaction, the chief financial officer now owns 18,167 shares of the company’s stock, valued at approximately $6,176,961.67. The disclosure for this sale can be found here. Insiders sold 24,923 shares of company stock valued at $8,397,380 in the last quarter. 1.20% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: Neutral Rating

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.